Vision-Sciences, Inc. Announces Completion Of $10.5 Million Common Stock Private Placement; $2.7 Million In Revenue For The Third Quarter Of Fiscal 2011
ORANGEBURG, N.Y., Jan. 18, 2011 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc., (Nasdaq:VSCI) (Vision-Sciences), announced today that it entered into common stock purchase agreements with a limited number of private investors for the sale of 7 million shares of Vision-Sciences' Common Stock at a purchase price of $1.50 per share, for a total cash consideration of $10,500,000. Vision-Sciences intends to use the net proceeds from the private placement for general corporate purposes.
Vision-Sciences also announced $2.7 million in net sales for its third quarter of fiscal 2011, ended December 31, 2010, a sequential growth rate of 17%, or $0.4 million, over net sales of $2.3 million for the second quarter of fiscal 2011. Year-over-year net sales grew $0.1 million, or 4%, from $2.6 million for the third quarter of fiscal 2010; pro forma for the exclusion of sales to Medtronic, net sales grew $1.1 million, or 66%, from $1.6 million for the third quarter of fiscal 2010. (Effective April 1, 2010, Medtronic no longer served as distributor of Vision-Sciences' ENT, or "ear, nose and throat," endoscopes).
Lewis C. Pell, Chairman of Vision-Sciences, stated, "I am extremely pleased that Vision-Sciences was able to raise over $10 million in this market. We believe the success of this private placement demonstrates investor enthusiasm for Vision-Sciences' progress, represented by over 65% growth over last year's third quarter (pro forma for the exclusion of sales to Medtronic) and by the Company's success in selling to leading teaching hospitals and other large accounts."Vision-Sciences expects to issue results for the third quarter and first nine months of its fiscal year 2011, ended December 31, 2010, during the week of February 7, 2011, at which time the Company plans to host a conference call to discuss these results. Forward Looking Statements Except for the historical information provided, the matters discussed in this release include forward-looking statements for the purposes of the safe harbor protections under The Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as Vision-Sciences or its management "believes," "expects," "allows," "anticipates," or other words or phrases of similar import. Similarly, statements in this release that describe our business strategy, outlook, objectives, plans, intentions, or goals are also forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those in forward-looking statements. Other risk factors are detailed in our most recent annual report and other filings with the Securities and Exchange Commission. We do not assume any obligation to update any forward-looking statements as a result of new information or future events or developments.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.